Ebe, Koji Takao Hospital|Japan Low Carbohydrate Diet Promotion Association
Bando, Hiroshi Japan Low Carbohydrate Diet Promotion Association|Tokushima University KAKEN Search Researchers
Muneta, Tetsuo Japan Low Carbohydrate Diet Promotion Association|Muneta Maternity Clinic
Bando, Masahiro Tokushima University
Yonei, Yoshikazu Doshisha University
Glutamic acid decarboxylase antibody (GADA)
Slowly-progressive type 1 diabetes (SPIDDM)
Glucose variability Type 2 diabetes mellitus (T2DM)
M value Low Carbohydrate Diet (LCD)
Background: Authors and collaborators have continued clinical research for Low Carbohydrate Diet (LCD) and Calorie Restriction Diet (CRD), glucose variability and M value. We investigated patients with Type 2 Diabetes Mellitus (T2DM) with positive Glutamic Acid Decarboxylase Antibody (GADA).
Subjects and methods: Subjects were 12 patients with T2DM showing positive GADA (group 1). They were given CRD on day 1,2, and LCD on day 3-14. Daily profile of blood glucose was measured each day, and data were calculated to M value expressing average glucose and Mean Amplitude of Glycemic Excursions (MAGE). Further, 12 T2DM cases with negative GADA were recruited, who were age-, sex-glucose-related data-matched (group 2).
Results: Data of group 1 were as follows: age 54.9 ± 14.3 yo, HbA1c 7.1 ± 0.9%, average blood glucose and M value on day 2 vs 4 were 187 (157-255) vs 145 (114-172), 76.9 (45.9-278) vs 27.2 (19.3-83.5), respectively. In group 2, M value on day 2 vs 4 were 69.9 (37.8-149) vs 5.8 (3.5-13.3), respectively. Group 1 showed insufficient decreased glucose in M value.
Discussion and conclusion: These results suggested that cases with positive GADA would have insufficient insulin secretion in response to LCD, and may lead to Slowly Progressive Insulin-Dependent Diabetes Mellitus (SPIDDM) status in the future.
Endocrinology and Metabolism : Open Access
© 2019 Ebe K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|URL ( Publisher's Version )|
emoa_3_1_115.pdf 419 KB